<DOC>
	<DOC>NCT00321620</DOC>
	<brief_summary>The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (ZometaÂ®) in the treatment of bone metastases in men with hormone-refractory prostate cancer</brief_summary>
	<brief_title>Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Men &gt;/= 18 years of age with histologically confirmed prostate cancer Radiographic evidence of at least one bone metastasis Failure of at least one hormonal therapy as evidenced by a rising PSA Serum testosterone level of &lt;50 ng/dL ECOG PS 0, 1, or 2 Adequate organ function Current or prior IV bisphosphonate administration Current or prior oral bisphosphonates for bone mets Life expectancy of less than 6 months</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Bone metastases</keyword>
	<keyword>Hormone-refractory prostate cancer</keyword>
	<keyword>Skeletal</keyword>
	<keyword>Fractures</keyword>
	<keyword>Compressions</keyword>
	<keyword>Bisphosphonates</keyword>
</DOC>